Inmunotek dedicates a large percentage of its income to R&D.
Its R&D team comprises top researchers who work on various technological development, innovation and research projects. The R&D department has well equipped labs of proteomics, molecular biology and immunology.
Inmunotek R&D lines focus on allergy and immunology (allergens, immunotherapy, immunomodulators, tumor markers, anti-neoplasic vaccines) and on the development of IT tools for clinical applications.
Our motto, Innovating and Sharing Ideas, represents our focus on dynamic research open to cooperation with other groups and companies.
At present, Inmunotek is involved in several active projects with researchers from the Complutense University (Madrid), The San Carlos Clinical Hospital (Madrid) and the King Faisal Hospital & Research Centre (Riyadh).
It also is a member of the ViVac European consortium (7th Framework Program) together with institutions from Sweden (Vicogel AB) and Norway (Lytix Biopharma), with the cooperation of the Karolinska Institute (Sweden), the Norwegian University of Science and Technology (Norway) and Hacettepe University (Turkey).